Effects of Gonadotropin and Testosterone Treatments on Prostate Volume and Serum Prostate Specific Antigen Levels in Male Hypogonadism.

Özata, Metịn; Bulur, Mertol; Beyhan, Zeynel; Şengül, Ali; Sağlam, Mutlu; Turan, Mustafa; Çorakçı, Ahmet; Gundogan, M. Ali

doi:10.1507/endocrj.44.719

Cited by 17 publications

(14 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study suggests that administration of exogenous testosterone to middle‐aged and older men with sexual and/or urinary dysfunction symptoms may retard or reverse age‐related prostate growth. Previous studies of the effects of exogenous testosterone on prostate size and PSA concentrations are mostly limited to hypogonadal men (Canale et al ., 1990; Sasagawa et al ., 1990; Behre et al ., 1994; Meikle et al ., 1997; Ozata et al ., 1997; Snyder et al ., 2000; Jin et al ., 2001). Generally these have shown that testosterone administration increases prostate volume from subnormal to age‐appropriate (Behre et al ., 1994) or smaller (Jin et al ., 2001) prostate volumes.…”

Section: Discussionmentioning

confidence: 99%

Androgen administration in middle‐aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume

et al. 2002

View full text Add to dashboard Cite

The gradual reduction of plasma testosterone in middle-aged and older men from mid-life onwards coincides paradoxically with the time when there is progressive growth of the prostate, a highly androgen-dependent organ. The growing interest in androgen therapy for older men makes it essential to understand the effects of exogenous testosterone on the non-diseased prostate, yet few studies are available. The present study examined prostate volume, prostate-specific antigen (PSA) and lower urinary tract symptom (IPSS) score in 207 men, aged 40-83 years, presenting with clinical features of age-related androgen deficiency [sexual and/or urinary dysfunction, elevated lutenizing hormone (LH)] who were treated for 6 months with oral testosterone undecanoate (TU). Men were divided into two groups, group 1 (n=92, plasma testosterone levels > 13 nmol/L) were treated with 80 mg daily; group 2 (n=115, plasma testosterone levels < 13 nmol/L) were treated with given 120 mg daily. Before treatment and after 1, 3 and 6 months of treatment, prostate volume was measured by ultrasound and hormones [testosterone, dihydrotestosterone, oestradiol, LH, follicle-stimulating hormone (FSH)] and PSA were measured. Within 1 month of treatment, the elevated blood LH levels were markedly decreased in all men in group 1, as well as most men in group 2. Group 2 was subdivided into men whose LH levels were suppressed (n=95, group 2a) and those whose LH levels did not suppress (n=20, group 2b). Men in group 1 and 2a had marked decreases in prostate volume, PSA and lower urinary tract symptom (IPSS) scores whereas no significant changes were observed in group 2b. Groups 1 and 2a also had more striking suppression of LH, FSH, dihydrotestosterone and oestradiol whereas group 2b had no significant increases in blood testosterone concentrations. These findings suggest that exogenous testosterone in middle-aged and older men with some clinical features of age-related androgen deficiency can retard or reverse prostate growth and that elevated plasma LH may be a useful index of severity of age-related androgen deficiency.

show abstract

Section: Discussionmentioning

confidence: 99%

Androgen administration in middle‐aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Effective treatment of hypogonadal men results in prostate volume and PSA levels comparable to age-matched normal men [23,24]. These modest, but consistent increases in PSA with TT treatment could suggest that elevation of serum TT levels, even within the normal range, can lead to stimulate prostate tissue [25].…”

Section: Discussion and Overall Conclusionmentioning

confidence: 94%

Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men

Raynaud

Legros

Rollet³

et al. 2008

The Journal of Steroid Biochemistry and Molecular Biology

View full text Add to dashboard Cite

“…Androgen deficiency is characterized by a decrease in prostate volume and serum PSA level. 19 Jin and colleagues have reported significantly lower testosterone and PSA levels in patients who were given androgen replacement therapy for androgen deficiency compared to patients with androgen deficiency who were not given androgen replacement therapy and also compared to healthy men. 20 Testosterone stimulates efficiency of prostatic epithelial cells which synthesize and secrete PSA.…”

Section: Discussionmentioning

confidence: 99%

The effects of cigarette smoking on prostate-specific antigen in two different age groups

Koç

Akgül

Yılmaz

et al. 2013

CUAJ

View full text Add to dashboard Cite

original research E704Cite as: Can Urol Assoc J 2013;7(11-12):e704-7. http://dx.doi.org/10.5489/cuaj.358 Published online November 8, 2013. AbstractBackground: We investigate the effects of cigarette smoking on prostate-specific antigen (PSA) using 2 different age groups. Methods: The study was carried out between January 2007 and October 2011 with men; the 2 sets of age groups were: 25 to 35 years and 50 to 70 years old. The participants were divided into 4 groups. Of the 25 to 35 age range, smokers were Group 1, and non-smokers were Group 2; of the 50 to 70 age range, smokers were Group 3 and non-smokers Group 4. In addition, for the 50 to 70 age group, the International Prostate Symptom Score was completed, digital rectal examination was performed, and transabdominal prostate volume was measured. We wanted to see whether prostate-specific antigen (PSA) levels showed a difference between the 2 age groups.

show abstract

Effects of Gonadotropin and Testosterone Treatments on Prostate Volume and Serum Prostate Specific Antigen Levels in Male Hypogonadism.

Cited by 17 publications

References 20 publications

Androgen administration in middle‐aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume

Androgen administration in middle‐aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume

Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men

The effects of cigarette smoking on prostate-specific antigen in two different age groups

Contact Info

Product

Resources

About